Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy
Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs ha...
Main Authors: | Weiwei Liu, Chaoqun Liu, Hui Wang, Lijun Xu, Jueyu Zhou, Sihua Li, Yu Cheng, Rui Zhou, Liang Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-01-01
|
Series: | Computational and Structural Biotechnology Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037022004202 |
Similar Items
-
Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy
by: Xianyong Zhou, et al.
Published: (2023-02-01) -
N6-methyladenosine methylation in kidney injury
by: Qimeng Wang, et al.
Published: (2023-10-01) -
The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors
by: Huan Tong, et al.
Published: (2022-01-01) -
Methyladenosine Modification in RNAs: Classification and Roles in Gastrointestinal Cancers
by: Qinghai Li, et al.
Published: (2021-02-01) -
Microenvironment modulation by key regulators of RNA N6-methyladenosine modification in respiratory allergic diseases
by: Yuting Wang, et al.
Published: (2023-06-01)